| abstract |
The present invention relates to a compound of formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of the prodrug. The compound interacts with CRF 1 receptors, including human CRF 1 receptor. The present invention provides for the treatment of CNS disorders or diseases, particularly anxiety related disorders such as anxiety, and mood disorders such as major depression, by using the compounds of the present invention to antagonize it. It also relates to a method of treating a disorder or condition that is promoted. |